Morgan upgrades Dasa to buy; shares surge; Hapvida target cut on legal costs

Morgan Stanley upgraded Dasa to buy, reinforcing preference for Raia Drogasil and Hypera, while cutting Hapvida's price target due to legal expenses hampering recovery. Dasa shares surged on the upgrade. The move signals a sector rotation within Brazilian healthcare, with legal costs weighing on Hapvida's outlook.